journal
MENU ▼
Read by QxMD icon Read
search

Liver Cancer

journal
https://www.readbyqxmd.com/read/29888210/hepatic-arterial-infusion-chemotherapy-a-potential-therapeutic-option-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#1
Michihisa Moriguchi, Takeshi Aramaki, Toshihiro Tanaka, Yoshito Itoh
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888209/successful-hepatic-arterial-infusion-of-chemotherapy-in-a-patient-with-advanced-hepatocellular-carcinoma-and-impending-liver-failure
#2
Tsung-Hao Liu, Chih-Hung Hsu, Yu-Yun Shao
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888208/risk-of-de-novo-hepatocellular-carcinoma-after-hcv-treatment-with-direct-acting-antivirals
#3
Fabian Finkelmeier, Georg Dultz, Kai-Henrik Peiffer, Bernd Kronenberger, Franziska Krauss, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, Oliver Waidmann
Background and Aims: The aim of the study was to evaluate the risk of hepatocellular carcinoma (HCC) development after treatment with direct-acting antivirals (DAAs) and to compare HCC occurrence in these patients with that among patients treated with interferon (IFN)-based therapies. Methods: We analyzed a large cohort with chronic hepatitis C virus patients for the onset of new HCC after DAA treatment. A historical IFN-treated cohort was investigated for comparison...
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888207/liver-transplantation-for-intermediate-stage-hepatocellular-carcinoma
#4
Naoko Kamo, Toshimi Kaido, Shintaro Yagi, Hideaki Okajima, Shinji Uemoto
Transarterial chemoembolization is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. However, in Japan, not a few patients with intermediate-stage HCC undergo liver transplantation (LT). The present study investigated characteristics and outcomes of LT for intermediate-stage HCC. Between February 1999 and November 2016, a total of 226 patients underwent LT for HCC at our institute. Among these, 56 patients showed intermediate-stage HCC (24...
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888206/a-phase-i-randomized-phase-ii-study-to-evaluate-the-safety-pharmacokinetics-and-efficacy-of-nintedanib-versus-sorafenib-in-asian-patients-with-advanced-hepatocellular-carcinoma
#5
Chia-Jui Yen, Tae-You Kim, Yin-Hsun Feng, Yee Chao, Deng-Yn Lin, Baek-Yeol Ryoo, Dennis Chin-Lun Huang, David Schnell, Julia Hocke, Arsène-Bienvenu Loembé, Ann-Lii Cheng
Background: Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor receptors. This randomized, multicenter, open-label, phase I/II study evaluated the safety, pharmacokinetics, maximum tolerated dose (MTD) in terms of dose-limiting toxicities (DLTs), and efficacy of nintedanib versus sorafenib in Asian patients with unresectable advanced hepatocellular carcinoma (HCC). Patients and Methods: For the phase I portion, patients were stratified into two groups according to their alanine aminotransferase/aspartate aminotransferase (ALT/AST) and Child-Pugh score at baseline...
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888205/regional-differences-in-efficacy-safety-and-biomarkers-for-second-line-axitinib-in-patients-with-advanced-hepatocellular-carcinoma-from-a-randomized-phase-ii-study
#6
Masatoshi Kudo, Yoon-Koo Kang, Joong-Won Park, Shukui Qin, Yoshitaka Inaba, Eric Assenat, Yoshiko Umeyama, Maria José Lechuga, Olga Valota, Yosuke Fujii, Jean-Francois Martini, J Andrew Williams, Shuntaro Obi
Background: An unmet need exists for treatment of patients with advanced hepatocellular carcinoma (HCC) who progress on or are intolerant to sorafenib. A global randomized phase II trial (ClinicalTrial.gov No. NCT01210495) of axitinib, a vascular endothelial growth factor receptor 1-3 inhibitor, in combination with best supportive care (BSC) did not prolong overall survival (OS) over placebo/BSC, but showed improved progression-free survival in some patients. Subgroup analyses were conducted to identify potential predictive/prognostic factors...
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888204/management-of-hepatocellular-carcinoma-in-japan-as-a-world-leading-model
#7
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29888203/cabozantinib-as-a-second-line-agent-in-advanced-hepatocellular-carcinoma
#8
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662837/patient-selection-for-transarterial-chemoembolization-in-hepatocellular-carcinoma-importance-of-benefit-risk-assessment
#9
REVIEW
Fabio Piscaglia, Sadahisa Ogasawara
Background: Liver cancer is the second most common cause of cancer-related death, with hepatocellular carcinoma (HCC) accounting for most primary liver cancers and most commonly arising from a history of advanced chronic liver disease. Among the available therapies, transarterial chemoembolization (TACE) is the most widely utilized and is considered the first-line treatment recommended for patients staged as intermediate HCC (Barcelona Clinic Liver Cancer stage B). If applied correctly, TACE can produce survival benefits without adversely affecting hepatic functional reserve...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662836/association-between-loss-of-skeletal-muscle-mass-and-mortality-and-tumor-recurrence-in-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#10
REVIEW
Ke-Vin Chang, Jin-De Chen, Wei-Ting Wu, Kuo-Chin Huang, Chia-Tzu Hsu, Der-Sheng Han
Background: Hepatocellular carcinoma (HCC) has multiple prognostic factors, and there is an increase in knowledge about the body composition and physical status of patients with HCC. The present meta-analysis aimed to explore whether loss of skeletal muscle mass is associated with mortality and tumor recurrence in patients with HCC. Method: A systematic search was conducted for published literature using PubMed, Embase, and Scopus. We included cohort or case-control studies investigating patients with HCC...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662835/preoperative-low-muscle-mass-and-low-muscle-quality-negatively-impact-on-pulmonary-function-in-patients-undergoing-hepatectomy-for-hepatocellular-carcinoma
#11
Hisaya Shirai, Toshimi Kaido, Yuhei Hamaguchi, Atsushi Kobayashi, Shinya Okumura, Siyuan Yao, Shintaro Yagi, Naoko Kamo, Kojiro Taura, Hideaki Okajima, Shinji Uemoto
Background: Sarcopenia is a prognostic factor for mortality in digestive surgery. However, the correlation between preoperative cardiopulmonary function and sarcopenia in patients undergoing hepatectomy for hepatocellular carcinoma (HCC) remains unclear. Methods: The present study investigated the impact of preoperative sarcopenia on cardiopulmonary function in 402 patients who underwent first hepatectomy for HCC between April 2005 and April 2015. The quantity and quality of skeletal muscle were evaluated using psoas muscle index (PMI) and intramuscular adipose tissue content (IMAC), respectively, as determined from preoperative computed tomography imaging...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662834/liver-stiffness-measured-by-two-dimensional-shear-wave-elastography-prognostic-value-after-radiofrequency-ablation-for-hepatocellular-carcinoma
#12
Dong Ho Lee, Jeong Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Jeong-Hoon Lee, Su Jong Yu, Joon Koo Han
Purpose: To evaluate the prognostic value of liver stiffness (LS) measured using two-dimensional (2D) shear-wave elastography (SWE) in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation (RFA). Methods: The Institutional Review Board approved this retrospective study and informed consent was obtained from all patients. A total of 134 patients with up to 3 HCCs ≤5 cm who had undergone pre-procedural 2D-SWE prior to RFA treatment between January 2012 and December 2013 were enrolled...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662833/short-term-outcomes-following-hepatectomy-in-elderly-patients-with-hepatocellular-carcinoma-an-analysis-of-10-805-septuagenarians-and-2-381-octo-and-nonagenarians-in-japan
#13
Hiroko Okinaga, Hideo Yasunaga, Kiyoshi Hasegawa, Kiyohide Fushimi, Norihiro Kokudo
Background: As the population is aging, the indication for hepatocellular carcinoma (HCC) resection in patients aged over 80 years will increase. Japan is facing the most aging society worldwide. We examined the safety of hepatectomy in octogenarians and nonagenarians using large-scale data from the Diagnosis Procedure Combination database, a national administrative database in Japan. Method: We conducted a survey to collect data for all inpatients from 2007 and 2012...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662832/hong-kong-consensus-statements-for-the-management-of-unresectable-hepatocellular-carcinoma
#14
Tom Tan-To Cheung, Philip Chong-Hei Kwok, Stephen Chan, Chin-Cheung Cheung, Ann-Shing Lee, Victor Lee, Hoi-Ching Cheng, Nam-Hung Chia, Charing C N Chong, Tak-Wing Lai, Ada L Y Law, Mai-Yee Luk, Chi Chung Tong, Thomas C C Yau
Background: Hepatocellular carcinoma (HCC) is highly prevalent in Hong Kong due to the high prevalence of chronic hepatitis B infection. Liver cancer is the fourth most common cancer and the third most common cause of cancer death. Due to the high case load, there is a high level of local expertise in treating HCC, and the full spectrum of treatment modalities is available. This document summarizes how these modalities should be used based on the latest evidence. Summary: In 2 meetings held in early 2017, a multidisciplinary group of Hong Kong clinicians, including liver surgeons, interventional radiologists, clinical oncologists, and medical oncologists, met to update local consensus statements for management of HCC...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662831/the-asia-pacific-consensus-statement-on-laparoscopic-liver-resection-for-hepatocellular-carcinoma-a-report-from-the-7th-asia-pacific-primary-liver-cancer-expert-meeting-held-in-hong-kong
#15
Tan To Cheung, Ho-Seong Han, Wong Hoi She, Kuo-Hsin Chen, Pierce K H Chow, Boon Koon Yoong, Kit Fai Lee, Shoji Kubo, Chung Ngai Tang, Go Wakabayashi
Background: Laparoscopic liver resection has been gaining momentum, and it has become an accepted practice after the two international consensus conferences where experts worked up guidelines to standardize this approach and improve its safety. However, most laparoscopic hepatectomies were performed in patients with liver metastases. The concurrent presence of liver cirrhosis with hepatocellular carcinoma (HCC) poses a great challenge to clinicians trying to establish a routine use of laparoscopic liver resection for HCC...
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662830/combination-cancer-immunotherapy-in-hepatocellular-carcinoma
#16
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29662829/lenvatinib-may-drastically-change-the-treatment-landscape-of-hepatocellular-carcinoma
#17
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
March 2018: Liver Cancer
https://www.readbyqxmd.com/read/29234641/albi-score-as-a-novel-tool-in-staging-and-treatment-planning-for-hepatocellular-carcinoma-advantage-of-albi-grade-for-universal-assessment-of-hepatic-function
#18
Atsushi Hiraoka, Kojiro Michitaka, Takashi Kumada, Masashi Kudo
No abstract text is available yet for this article.
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29234640/albi-score-as-a-novel-tool-in-staging-and-treatment-planning-for-hepatocellular-carcinoma-is-it-sufficient
#19
Teh-Ia Huo, Po-Hong Liu, Chia-Yang Hsu
No abstract text is available yet for this article.
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29234639/hepatocellular-carcinoma-with-macrovascular-invasion-defining-the-optimal-treatment-strategy
#20
REVIEW
Charlotte E Costentin, Cristina R Ferrone, Ronald S Arellano, Suvranu Ganguli, Theodore S Hong, Andrew X Zhu
Background: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. Summary: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib...
November 2017: Liver Cancer
journal
journal
47850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"